Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study
Adding penpulimab to chemotherapy more than doubled disease progression time in nasopharyngeal carcinoma patients with manageable side effects.
This phase 3 trial demonstrated that adding the PD-1 inhibitor penpulimab to standard chemotherapy more than doubled the time before disease progression in patients with recurrent/metastatic nasopharyngeal carcinoma. The safety profile was acceptable with immune-related serious adverse events in only 4.1% of the penpulimab arm.
What the study was
- Study design
- Phase 3, randomized, double-blind, placebo-controlled
- Population
- Recurrent or metastatic nasopharyngeal carcinoma patients, first-line
- Sample size
- 291
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Signal Transduction and Targeted Therapy
Why it surfaced
Phase 3 RCT showing significant PFS benefit for a new PD-1 inhibitor in first-line NPC; HR 0.45 is highly clinically meaningful and could change standard of care.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.